A Review on Benign Prostatic Hyperplasia

  • Dr. A. Kishorebabu Department of the Industrial Pharmacy, A.M. Reddy Memorial college of Pharmacy, Petlurivaripalem Guntur [dist] Andhrapradesh India,522601
    drakishorebabu@gmail.com
  • S. Navya Sree 3V Pharm D Department of pharmacy practice, A.M. Reddy memorial college of Pharmacy, Petlurivaripalem Guntur [dist], Andhrapradesh India, 522601
  • S. Purnima Chandralekha 3V Pharm D Department of pharmacy practice, A.M. Reddy memorial college of Pharmacy, Petlurivaripalem Guntur [dist], Andhrapradesh India, 522601

Abstract

Benign prostatic hyperplasia is the enlargement of prostate gland mainly seen in men aged above 50 years. It has been observed that 8 out of 10 men having prostate enlargement. It is mainly caused due to over growth of benign glandular tissue and leads to the constriction of urethra and decreased urine output. Diagnosis for BPH involves Obligatory and optional evaluation. The main risk factor for BPH is age.BPH is clinically manifested as obstructive LUTS (lower urinary tract symptoms) and irritable LUTS (lower urinary tract symptoms).Treatment for BPH depends on number of factors like age, prostate size, and severity of symptoms . Alpha1Adrenergic receptor antagonist decreased lower urinary symptoms and increased flow rates of urine in men with symptomatic BPH but do not reduce the long term risk of urinary retention. 5 alpha reductase inhibitors decrease the production of dihydrotestosterone with in the prostate which results in decreased prostate volume, increased peak urinary flow rate, improvement of symptoms, and decreased risk of acute urinary retention. Combination therapy involves 5 alpha reductase inhibitors and alpha adrenergic blockers it is effective in patients having LUTS with prostatic enlargement. Anticholinergics and phosphodiesterase inhibitors were also used in the management of BPH. Medication therapy is used in all the three stages but it only delays surgery in patients with severe BPH.

Keywords: Prostate enlargement, LUTS, 5Alpha reductase inhibitors, Alpha adrenergic blockers

Downloads

Download data is not yet available.

References

1 .https://www.niddk.nih.gov/health-information/urologic-diseases/prostate-problems/prostate-enlargement-benign-prostatic-hyperplasia#benign
2. https://www.radiologyinfo.org/en/info.cfm?pg=bph
3. https://www.niddk.nih.gov/health-information/urologic-diseases/prostate-problems/prostate-enlargement-benign-prostatic-hyperplasia
4. Australia and New Zealand Urological Nurses Society Inc . 2010. Management of male lower urinary tract symptoms (LUTS) and clinical practice guidelines.https://view.officeapps.live.com/op/view.aspx?src=http%3A%2F%2Fwww.anzuns.org%2FLUTS_guidelines_Urology_NP_updated_Jan_2010-2.DOC [Accessed 14 February 2017] [Google Scholar]
5.https://www.mayoclinic.org/diseases-conditions/benign-prostatic-hyperplasia/diagnosis-treatment/drc-20370093
6. Cotran RS, Kumar V, Robbins SL. Male genital system. In: Robbins Pathologic Basis of Disease. 5th ed. Philadelphia, Pa.: Saunders;1994.
7. https://consultqd.clevelandclinic.org/benign-prostatic-hyperplasia-evaluation-and-medical-management-in-primary-care/
8. https://www.urologyhealth.org/urologic-conditions/benign-prostatic-hyperplasia-(bph)
9. https://www.google.co.in/amp/s/consultqd.clevelandclinic.org/benign-prostatic-hyperplasia-evaluation-and-medical-management-in-primary-care/amp/
10. Kobayashi S, Tang R, Shapiro E, Lepor H. Characterization and localization of prostatic alpha 1 adrenoceptors using radioligand receptor binding on slide-mounted tissue section. J Urol 1993; 150:2002–2006
11. Kirby RS, Pool JL. Alpha adrenoceptor blockade in the treatment of benign prostatic hyperplasia: past, present and future. Br J Urol 1997; 80:521–532.
12. Kirby RS, Pool JL. Alpha adrenoceptor blockade in the treatment of benign prostatic hyperplasia: past, present and future. Br J Urol 1997; 80:521–532
13. 28. Lepor H, Auerbach S, Puras-Baez A, et al. A randomized, placebocontrolled multicenter study of the effi cacy and safety of terazosin in the treatment of benign prostatic hyperplasia. J Urol 1992; 148:1467–1474
14. McConnell JD, Roehrborn CG, Bautista OM, et al; Medical Therapy of Prostatic Symptoms (MTOPS) Research Group. The long-term effect of doxazosin, fi nasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med 2003; 349:2387–2398.
15. Gormley GJ, Stoner E, Bruskewitz RC, et al. The effect of fi nasteride in men with benign prostatic hyperplasia. The Finasteride Study Group. N Engl J Med 1992; 327:1185–1191.
16. Roehrborn CG, Boyle P, Nickel JC, Hoefner K, Andriole G; ARIA3001 ARIA3002 and ARIA3003 Study Investigators. Effi cacy and safety of a dual inhibitor of 5-alpha-reductase types 1 and 2 (dutasteride) in men with benign prostatic hyperplasia. Urology 2002; 60:434–441.
17. Kaplan SA, Lee JY, Meehan AG, Kusek JW; MTOPS Research Group. Long-term treatment with fi nasteride improves clinical progression of benign prostatic hyperplasia in men with an enlarged versus a smaller prostate: data from the MTOPS trial. J Urol 2011; 185:1369– 1373.
18. Roehrborn CG, Siami P, Barkin J, et al; CombAT Study Group. The effects of combination therapy with dutasteride and tamsulosin on clinical outcomes in men with symptomatic benign prostatic hyperplasia: 4-year results from the CombAT study. Eur Urol 2010; 57:123–131.
19. Abrams P, Kaplan S, De Koning Gans HJ, Millard R. Safety and tolerability of tolterodine for the treatment of overactive bladder in men with bladder outlet obstruction. J Urol 2006; 175:999–1004.
20.Kaplan SA, Roehrborn CG, Rovner ES, Carlsson M, Bavendam T, Guan Z. Tolterodine and tamsulosin for treatment of men with lower urinary tract symptoms and overactive bladder: a randomized controlled trial. JAMA 2006; 296:2319–2328.
21. https://www.urologyhealth.org/urologic-conditions/benign-prostatic-hyperplasia-(bph)
Statistics
119 Views | 76 Downloads
How to Cite
Kishorebabu, D. A., S. N. Sree, and S. P. Chandralekha. “A Review on Benign Prostatic Hyperplasia”. World Journal of Current Medical and Pharmaceutical Research, Vol. 1, no. 5, Nov. 2019, pp. 192-7, https://wjcmpr.com/index.php/journal/article/view/41.
Section
Review Articles